Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Deborah Collyar: What's In It for Patients?

Varsha Gandhi, PhD, on Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mar

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Deborah Collyar: What's In It for Patients?

Varsha Gandhi, PhD, on Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care

Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis

Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer

Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence